AN 8025
Alternative Names: AN-8025Latest Information Update: 27 Aug 2024
Price :
$50 *
At a glance
- Originator Adlai Nortye
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Aug 2024 Preclinical trials in Solid tumours in China (unspecified route) prior to August 2024 (Adlai Nortye pipeline, August 2024)
- 08 Aug 2024 Adlai Nortye announces intention to submit an IND application in mid 2025
- 06 Oct 2022 Early research in Solid tumours in China (Adlai Nortye pipeline, October 2022)